

# Estela Pineda-Losada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9909303/publications.pdf>

Version: 2024-02-01

36  
papers

1,582  
citations

759055

12  
h-index

526166

27  
g-index

36  
all docs

36  
docs citations

36  
times ranked

3215  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical implications of the intrinsic molecular subtypes of breast cancer. <i>Breast</i> , 2015, 24, S26-S35.	0.9	735
2	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019, 10, 2416.	5.8	150
3	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , 2018, 24, 2812-2819.	3.2	128
4	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O <sup>6</sup> -Methylguanineâ€DNA Methyltransferase Biomarker Analyses. <i>Journal of Clinical Oncology</i> , 2017, 35, 343-351.	0.8	110
5	A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples. <i>PLoS ONE</i> , 2017, 12, e0170632.	1.1	100
6	A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). <i>Neuro-Oncology</i> , 2020, 22, 1851-1861.	0.6	64
7	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. <i>Cell Reports</i> , 2017, 21, 2183-2197.	2.9	56
8	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. <i>Nature Communications</i> , 2021, 12, 1503.	5.8	45
9	Pseudoprogression as an adverse event of glioblastoma therapy. <i>Cancer Medicine</i> , 2017, 6, 2858-2866.	1.3	44
10	Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2015-2015.	0.8	25
11	MET inhibitors in cancer: pitfalls and challenges. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 73-85.	1.9	16
12	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9069-9069.	0.8	15
13	Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT. <i>Journal of Clinical Medicine</i> , 2021, 10, 2131.	1.0	13
14	LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET. <i>Molecular Carcinogenesis</i> , 2016, 55, 411-419.	1.3	11
15	Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. <i>Tumor Biology</i> , 2017, 39, 101042831770550.	0.8	10
16	Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6600-6609.	3.2	10
17	Development of Randomized Trials in Adults with Medulloblastomaâ€The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	1.7	8
18	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial. <i>Cancers</i> , 2022, 14, 2393.	1.7	8

#	ARTICLE	IF	CITATIONS
19	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. <i>ESMO Open</i> , 2016, 1, e000032.	2.0	7
20	Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab. <i>Neuro-Oncology Practice</i> , 2017, 4, 15-23.	1.0	6
21	SEOM clinical guideline for management of adult medulloblastoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 940-947.	1.2	6
22	RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP negative Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 645-655.	3.2	5
23	Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3048-3048.	0.8	5
24	Romiplostim for the treatment of glioblastoma-related paraneoplastic autoimmune thrombocytopenia refractory to conventional therapy. <i>Annals of Hematology</i> , 2016, 95, 665-666.	0.8	2
25	Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy. <i>Journal of Neuro-Oncology</i> , 2018, 139, 779-780.	1.4	1
26	Do we need adjuvant therapy in rectal cancer with complete pathologic response (ypT0N0) after induction chemoradiation and laparoscopic mesorectal excision?. <i>Journal of Clinical Oncology</i> , 2012, 30, 3536-3536.	0.8	1
27	Gene expression profiling of glioblastoma (GBM) in an homogeneous treated population: Correlation with immunohistochemistry, radiology, clinical outcome, and response to therapy. A multicenter study from the GLIOCAT group, Marato TV3 2012, project 665/c/2013.. <i>Journal of Clinical Oncology</i> , 2016, 34, e13515-e13515.	0.8	1
28	Clinical outcomes in BRAFV600-mutant metastatic melanoma with sequential treatment with immunotherapy and BRAF inhibitors or vice versa.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20030-e20030.	0.8	0
29	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14552-e14552.	0.8	0
30	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3033-3033.	0.8	0
31	Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 66-66.	0.8	0
32	Galectin-1 (Gal-1) expression as a prognostic factor in patients with newly diagnosed glioblastoma (GB) treated with Stupp regimen (GLIOCAT study).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13526-e13526.	0.8	0
33	A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors in adulthood (GETH021).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3123-TPS3123.	0.8	0
34	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3076-3076.	0.8	0
35	Is IDO1 an adequate target for treatment in glioblastoma?. <i>Journal of Clinical Oncology</i> , 2022, 40, e14039-e14039.	0.8	0
36	Safety and efficacy of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2060-2060.	0.8	0